Drug intelligence & clinical pharmacy最新文献_第9页

Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension. 依那普利与氢氯噻嗪治疗老年轻中度高血压的比较评价。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200905

J G Gums, L M Lopez, G P Quay, G H Stein, D L McCarley

{"title":"Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension.","authors":"J G Gums, L M Lopez, G P Quay, G H Stein, D L McCarley","doi":"10.1177/106002808802200905","DOIUrl":"https://doi.org/10.1177/106002808802200905","url":null,"abstract":"Initial treatment of elderly hypertensive patients with an angiotensin-converting enzyme inhibitor is currently discouraged due to such patients' typical low-renin profile. To validate this principle, we studied 38 elderly males (aged greater than or equal to 65 years) with mild to moderate hypertension, comparing hemodynamic responses to and subjective impressions of enalapril or hydrochlorothiazide (HCTZ). After gradual withdrawal of existing antihypertensive therapy and a four-week, single-blind placebo period, each patient was randomized in a double-blind fashion to receive either enalapril 10-20 mg/d or HCTZ 12.5-25 mg/d for two to four weeks. Combination therapy with both agents was employed if either alone failed to reduce seated diastolic BP to less than or equal to 90 mm Hg. Equivalent proportions of patients receiving enalapril or HCTZ (8 of 19 and 10 of 19, respectively; p = ns) responded with significant reductions in systolic and diastolic BP in seated and standing positions. Combination therapy was most effective in patients receiving HCTZ prior to enalapril. In patients receiving enalapril before HCTZ, BP changes were minimal. No adverse effects were observed in the enalapril group but occurred in an equivalent fraction of patients in the other groups (4 of 10 HCTZ alone, 6 of 20 enalapril + HCTZ; p = ns). We conclude that enalapril may be considered a reasonable monotherapeutic antihypertensive agent in some elderly patients. Combination with HCTZ is beneficial in patients who fail to respond adequately to HCTZ alone.","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 9","pages":"680-4"},"PeriodicalIF":0.0,"publicationDate":"1988-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802200905","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13988827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Estrogen priming in advanced breast cancer. 雌激素在晚期乳腺癌中的作用。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200903

M Maghsoodnia, W M Holleran, M W DeGregorio

引用次数: 0

Patient tolerance to intravenous potassium chloride with and without lidocaine. 患者对静脉注射氯化钾加利多卡因和不加利多卡因的耐受性。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200904

F Pucino, B D Danielson, J D Carlson, G L Strommen, P R Walker, C L Beck, D J Thiege, D S Gill

{"title":"Patient tolerance to intravenous potassium chloride with and without lidocaine.","authors":"F Pucino, B D Danielson, J D Carlson, G L Strommen, P R Walker, C L Beck, D J Thiege, D S Gill","doi":"10.1177/106002808802200904","DOIUrl":"https://doi.org/10.1177/106002808802200904","url":null,"abstract":"Hypokalemia is a common electrolyte abnormality. Intravenous repletion therapy with potassium chloride (KCl) in concentrations greater than 80-100 mEq/L is not recommended due to patient intolerance. Since this guideline at times may be clinically impractical, this study was designed to examine use of peripheral vein infusions of high concentration KCl therapy. Tolerance to KCl 20 mEq/65 ml iv with and without lidocaine 50 mg was evaluated in 18 hypokalemic subjects in a randomized, placebo-controlled, double-blind study. Subjective and objective assessments of adverse effects were determined throughout the infusion period. Pain was assessed by both verbal descriptor and visual analog scales and correlated significantly following infusion of KCl with or without lidocaine. Multivariant analysis demonstrated differences in pain perception between solutions, with significantly less pain following KCl with lidocaine versus KCl infusions. Transient adverse effects occurred in both groups, but the incidence was not statistically different. Use of concentrated iv KCl infusions may benefit hypokalemic patients with hypervolemia and/or severe potassium deficits. Addition of lidocaine clearly improves patient tolerance to intravenous KCl replacement.","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 9","pages":"676-9"},"PeriodicalIF":0.0,"publicationDate":"1988-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802200904","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14196175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Drug package information in India. 印度药品包装信息。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200918

M C Nahata

引用次数: 2

Midazolam disinhibition reaction. 咪达唑仑去抑制反应。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200924

B L Lobo, L J Miwa

引用次数: 21

Extreme warfarin intoxication secondary to possible covert drug ingestion. 严重华法林中毒继发于可能的隐蔽药物摄入。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200910

R G Richmond, W T Sawyer, P D Aiello, C M Lindley

引用次数: 3

Therapeutic drug interchange: the battle heats up. 治疗药物交换:战斗白热化。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200917

D C McLeod

{"title":"Therapeutic drug interchange: the battle heats up.","authors":"D C McLeod","doi":"10.1177/106002808802200917","DOIUrl":"https://doi.org/10.1177/106002808802200917","url":null,"abstract":"THERAPEUTIC INTERCHANGE! The battlelines have been reconnoitered and the major protagonists and antagonists are headed for the front. The old nemesis \"substitution\" has been dressed up as \"interchange:' ~hey are in fact equivalent terms in this therapeutic field of battle. As health professionals we are so used to making war on cancer, battling AIDS, holding the line ?~ arthritis, ,and bombarding malaria-infested jungles, It IS no surpnse that we struggle tenaciously for a limited health care turf and love to do a little interprofessional skull-bashing on Saturday nights. Therapeutic interchange is a far more explosive issue than generic interchange, which still causes propaganda ~arfare after almost 20 years of enabling state legislanon encouraged by the American Pharmaceutical Association (APhA). Generic interchange occurs only after patent expiration. Therapeutic interchange can result in the substitution of another chemical entity, on or off patent, for a substance still under patent protection, even a newdrug just reaching the market after costly research and development. Expensive sales forces, clever and extensive marketing strategies, and decades of company image-building can be thwarted overnight, the pharmaceutical industry fears, if therapeutic substitution is carried to its possible conclusion. The debate has suddenly escalated an order of magnitude due to a position taken by the American Association of Colleges of Pharmacy (AACP), a respected organization representing academic pharmacy, many of who~e memb~r~ are generally pro-industry and supportive of positrons taken by the Pharmaceutical Manufacturers Association (PMA). The following is from the AACP News:","PeriodicalId":77709,"journal":{"name":"Drug intelligence & clinical pharmacy","volume":"22 9","pages":"716-8"},"PeriodicalIF":0.0,"publicationDate":"1988-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/106002808802200917","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14342976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Marked digoxin-like immunoreactive factor interference with an enzyme immunoassay. 地高辛样免疫反应因子明显干扰酶免疫测定。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200913

J A Karboski, P J Godley, P A Frohna, M W Horton, W J Reitmeyer

引用次数: 7

Soft-tissue damage and intravenous phenytoin. 软组织损伤，静脉注射苯妥英。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200925

D Grinder, C P Guastella, M Pellegrino

引用次数: 5

Unique two-stage intervention to modify prescribing trends. 独特的两阶段干预改变处方趋势。

Drug intelligence & clinical pharmacy Pub Date : 1988-09-01 DOI: 10.1177/106002808802200926

S Gupta, R L Bachand, P J Jewesson

引用次数: 4